TY  - JOUR
AU  - Gajjar, Amar
AU  - Robinson, Giles W
AU  - Smith, Kyle S
AU  - Lin, Tong
AU  - Merchant, Thomas E
AU  - Chintagumpala, Murali
AU  - Mahajan, Anita
AU  - Su, Jack
AU  - Bouffet, Eric
AU  - Bartels, Ute
AU  - Schechter, Tal
AU  - Hassall, Tim
AU  - Robertson, Thomas
AU  - Nicholls, Wayne
AU  - Gururangan, Sridharan
AU  - Schroeder, Kristin
AU  - Sullivan, Michael
AU  - Wheeler, Greg
AU  - Hansford, Jordan R
AU  - Kellie, Stewart J
AU  - McCowage, Geoffrey
AU  - Cohn, Richard
AU  - Fisher, Michael J
AU  - Krasin, Matthew J
AU  - Stewart, Clinton F
AU  - Broniscer, Alberto
AU  - Buchhalter, Ivo
AU  - Tatevossian, Ruth G
AU  - Orr, Brent A
AU  - Neale, Geoff
AU  - Klimo, Paul
AU  - Boop, Frederick
AU  - Srinivasan, Ashok
AU  - Pfister, Stefan M
AU  - Gilbertson, Richard J
AU  - Onar-Thomas, Arzu
AU  - Ellison, David W
AU  - Northcott, Paul A
TI  - Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
JO  - Journal of clinical oncology
VL  - 39
IS  - 7
SN  - 1527-7755
CY  - Alexandria, Va.
PB  - American Society of Clinical Oncology
M1  - DKFZ-2021-00042
SP  - 822-835
PY  - 2021
N1  - 2021 Mar 1;39(7):822-835
AB  - SJMB03 (ClinicalTrials.gov identifier: NCT00085202) was a phase III risk-adapted trial that aimed to determine the frequency and clinical significance of biological variants and genetic alterations in medulloblastoma.Patients 3-21 years old were stratified into average-risk and high-risk treatment groups based on metastatic status and extent of resection. Medulloblastomas were molecularly classified into subgroups (Wingless [WNT], Sonic Hedgehog [SHH], group 3, and group 4) and subtypes based on DNA methylation profiles and overlaid with gene mutations from next-generation sequencing. Coprimary study end points were (1) to assess the relationship between ERBB2 protein expression in tumors and progression-free survival (PFS), and (2) to estimate the frequency of mutations associated with WNT and SHH tumors. Clinical and molecular risk factors were evaluated, and the most robust were used to model new risk-classification categories.Three hundred thirty eligible patients with medulloblastoma were enrolled. Five-year PFS was 83.2
LB  - PUB:(DE-HGF)16
C6  - pmid:33405951
DO  - DOI:10.1200/JCO.20.01372
UR  - https://inrepo02.dkfz.de/record/166689
ER  -